Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.34 |
| ▸ | MAP2K1 | Q02750 | 3/20 | 0.34 |
| ▸ | RAF1 | P04049 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2388265 | 0.76 | CXCR3 (0.50) | HDAC6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL3956974 | 0.71 | HDAC6 (0.58) | HDAC6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL15648265 | 0.71 | HDAC6 (0.52) | HDAC6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL2393127 | 0.70 | CHEK1 (0.39) | HDAC6HDAC8KMT2AMEN1TP53 | |
| SCHEMBL2394882 | 0.69 | PRMT5 (0.41) | HDAC6HDAC3HDAC1HDAC8KMT2A | |
| SCHEMBL16663613 | 0.69 | HDAC6 (0.59) | HDAC6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL22919775 | 0.69 | HDAC6 (0.59) | HDAC6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL11935144 | 0.68 | CXCR4 (0.56) | KMT2AMEN1TP53CYP3A4CYP2D6 | |
| SCHEMBL2393068 | 0.68 | MAP2K1 (0.30) | MAP2K1RAF1PDGFRBCSNK2A2MAP2K2 | |
| SCHEMBL27694180 | 0.67 | AKR1B1 (0.48) | CYP2C9CYP2C19AKR1B1MAP2K1MAP2K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9051279-B2 | Substituted isoquinolinones and quinazolinones | NOVARTIS AG (CH) | 2015-06-09 | — | — | US | disclosed |
| EP-2516009-B1 | SUBSTITUTED ISOQUINOLINONES AND QUINAZOLINONES | NOVARTIS AG (CH) | 2014-09-24 | — | — | EP | disclosed |
| US-20130281473-A1 | SUBSTITUTED ISOQUINOLINONES AND QUINAZOLINONES | NOVARTIS AG (CH) | 2013-10-24 | — | — | US | disclosed |
| US-8440693-B2 | Substituted isoquinolinones and quinazolinones | NOVARTIS AG (CH) | 2013-05-14 | — | — | US | disclosed |
| EP-2516009-A1 | SUBSTITUTED ISOQUINOLINONES AND QUINAZOLINONES | Novartis AG (CH) | 2012-10-31 | — | — | EP | disclosed |
| US-20110230457-A1 | Substituted Isoquinolinones and Quinazolinones | NOVARTIS AG (CH) | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230457-A1 | Substituted Isoquinolinones and Quinazolinones | MDM4, MDM2, TP53 | HDAC6 1090/4885HDAC3 1066/4885HDAC1 550/4885 |
| US-20130281473-A1 | SUBSTITUTED ISOQUINOLINONES AND QUINAZOLINONES | MDM4, MDM2, TP53 | HDAC6 1090/4885HDAC3 1066/4885HDAC1 550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.